Dr. Reddy's Laboratories Limited
NYSEDr. Reddy's Laboratories reports again on July 24 — but for the ADR, the real verdict is already in the price. The stock bounced 3.7% on July 23 to $11.80, a partial recovery after the 9.4% one-day collapse that followed the Q1 print on July 22. The one-month decline still reaches 15.2%, and the week remains down 7.1%. That single-session rebound has loosened availability somewhat…
Dr. Reddy's Laboratories reports again on July 24 — but for the ADR, the real verdict is already in the price. The stock bounced 3.7% on July 23 to $11.80, a partial recovery after the 9.4% one-day collapse that…
Dr. Reddy's Laboratories has moved sharply lower in the session following its Q1 print, and the positioning story that dominated the pre-earnings setup is now being tested by hard price action. The market's response…
Snapshot as of 6 Aug 2026
Dr. Reddy's Laboratories reports Q1 results on July 22 against a backdrop of easing short pressure and cautious options activity — a setup where the positioning story and the fundamental debate are pulling in opposite…
Dr. Reddy's Laboratories heads into today's June 17 earnings release with the same structural tension that has defined this entire preview cycle — but the borrow market has tightened sharply since the June 13 article,…
Dr. Reddy's Laboratories arrives at its June 16 earnings release with the defining feature of this preview cycle now more pronounced than at any prior print: the short position has broken out to a new high, even as…
Dr. Reddy's Laboratories arrives at its June 10 print with the same structural split that has defined this entire preview cycle — but the lending market has shifted materially since the last article. The most notable…
Dr. Reddy's Laboratories carries the same structural divide into its June 9 print that has defined this entire preview cycle — short sellers sitting near their highs, options traders showing no concern whatsoever. The…
Dr. Reddy's Laboratories arrives at its June 5 earnings release carrying the same stubborn split that has defined this entire preview cycle — though the data has shifted under both camps since yesterday's article. The…
Dr. Reddy's Laboratories reaches its June 3 earnings release with the same structural divide that has defined this entire preview cycle — short sellers entrenched near cycle highs, options traders resolutely…
Dr. Reddy's Laboratories heads into its June 2 results with the same structural divide that has run through this entire preview cycle — short sellers still elevated, options traders still unbothered — though the short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RDY — free to start on ORTEX.
Sign up for free →Open RDY on ORTEX